Dupont Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Dupont Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,498	Closed	-$139K	–	850
2022 Q4	$139K	Sell	7,498 -10,704	-59%	-$165K	0.01%	872
2022 Q3	$234K	Sell	18,202 -28,557	-61%	-$338K	0.01%	843
2022 Q2	$328K	Hold	46,759	–	–	0.02%	843
2022 Q1	$388K	Sell	46,759 -4,136	-8%	-$29.2K	0.02%	866
2021 Q4	$345K	Sell	50,895 -20,292	-29%	-$133K	0.01%	931
2021 Q3	$377K	Sell	71,187 -10,062	-12%	-$55K	0.01%	999
2021 Q2	$467K	Hold	81,249	–	–	0.01%	1039
2021 Q1	$375K	Sell	81,249 -16,663	-17%	-$66.2K	0.01%	1068
2020 Q4	$327K	Sell	97,912 -7,307	-7%	-$24.5K	0.01%	1010
2020 Q3	$313K	Buy	+105,219	New	+$411K	0.01%	954

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dupont Capital Management's CPRX Position: Q1 2023 in Review

Dupont Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 7,498 shares — an estimated $139K sold.

Dupont Capital Management first reported a position in CPRX in Q3 2020 and held it in 10 quarters. The position peaked at $467K in Q2 2021. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

Dupont Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Dupont Capital Management sold 7,498 Catalyst Pharmaceutical shares in Q1 2023, an estimated $139K.
Dupont Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2020 and held it in 10 quarters.
Dupont Capital Management's Catalyst Pharmaceutical position peaked at $467K in Q2 2021.
259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.